Comparative Pharmacology
Head-to-head clinical analysis: CEFOXITIN IN PLASTIC CONTAINER versus KEFUROX IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOXITIN IN PLASTIC CONTAINER versus KEFUROX IN PLASTIC CONTAINER.
CEFOXITIN IN PLASTIC CONTAINER vs KEFUROX IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefoxitin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP1a, PBP1b, and PBP2, thereby inhibiting transpeptidation and leading to cell lysis. It is a cephamycin antibiotic resistant to beta-lactamase hydrolysis due to a 7-alpha-methoxy group.
Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-3 and PBP-1a/1b, leading to inhibition of transpeptidase activity and autolysin-mediated cell death.
1-2 g IV every 6-8 hours; maximum 12 g/day
750 mg to 1.5 g IV every 8 hours; for severe infections, up to 3 g IV every 8 hours.
None Documented
None Documented
Terminal elimination half-life: 0.7-1.5 hours (approximately 45-90 minutes); prolonged to 2-6 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 10-20 hours in severe renal impairment (CrCl <10 mL/min).
1.2-1.6 hours in adults with normal renal function. Extended to 15-22 hours in end-stage renal disease.
Renal: 85-95% unchanged via glomerular filtration and tubular secretion; biliary: <2%; fecal: trace.
Renal: 80-90% unchanged by glomerular filtration and tubular secretion. Biliary: <2% excreted in bile. Fecal: <1%.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic